Metabolomics and Lipidomics Reveal Systemic Metabolic Remodeling in Growth Hormone Deficiency
Background
Growth Hormone Deficiency (GHD) is a systemic endocrine-metabolic disorder impacting body composition, protein turnover, lipid mobilization, and cardiometabolic physiology. Untreated GHD in adults leads to increased adiposity, reduced lean mass, and impaired physical and metabolic function. Current diagnostic methods, including GH stimulation tests and IGF-1 concentrations, have limitations in fully defining the metabolic state of GH-responsive tissues. This creates a gap in understanding the comprehensive metabolic remodeling associated with GHD.
Why It Matters
While specific findings are not detailed here, a study leveraging metabolomics and lipidomics in Growth Hormone Deficiency (GHD) holds significant promise. Uncovering the precise systemic metabolic remodeling could lead to novel diagnostic biomarkers, offering a more comprehensive assessment of GHD beyond traditional GH/IGF-1 levels. This deeper understanding might guide personalized therapeutic approaches, potentially optimizing GH replacement strategies or identifying adjunctive treatments to mitigate specific metabolic complications. Such insights could refine clinical protocols, ensuring more targeted and effective management of GHD's broad metabolic impact.
growth hormone deficiency
ghd
growth hormone
gh
metabolomics
lipidomics
